Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
Cancer Investigation|October 21, 2011
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancerNan Soon Wong, Kellen L Meadows, Lee S Rosen, et al.
Toxicologic Pathology|February 28, 2007
Detection of pre-invasive lung cancer: technical aspects of the LIFE projectGordon P Flake, M Patricia Rivera, William K Funkhouser, et al.
Cancer Chemotherapy and Pharmacology|February 27, 2017
Phase I study of pazopanib plus TH-302 in advanced solid tumorsRichard F Riedel, Kellen L Meadows, Paula H Lee, et al.
Cancer Chemotherapy and Pharmacology|June 30, 2012
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumorsJohn H Strickler, Alexander N Starodub, Jingquan Jia, et al.
Biophysical Journal|February 21, 2012
Temperature-induced transitions in the structure and interfacial rheology of human meibumDanielle Leiske, Danielle L Leiske, Christopher Leiske, et al.
American Journal of Human Genetics|February 11, 1999
Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs populationD C Crawford, K L Meadows, J L Newman, et al.
Circulation|June 28, 2013
Stress cardiac magnetic resonance imaging provides effective cardiac risk reclassification in patients with known or suspected stable coronary artery diseaseRavi Shah, Bobak Heydari, Otavio Coelho-Filho, et al.
Cancer Chemotherapy and Pharmacology|May 29, 2012
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumorsGordana Vlahovic, Kellen L Meadows, Hope E Uronis, et al.
The International Journal of Cardiovascular Imaging|February 22, 2019
Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathySyed R Latif, Vinh Q Nguyen, Dana C Peters, et al.
Investigational New Drugs|November 1, 2013
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancerJohn H Strickler, Shannon McCall, Andrew B Nixon, et al.
Pageof 13